Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Sun Yat-sen University: Clinical Trials & FDA Approval Profile

Sun Yat-sen University (Global / Institutional) sponsors 665 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 365 active protocols (196 recruiting now), 60 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)4.5%
Median Closed Enrollment vs National (145 pts)54 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Sun Yat-sen University
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)665
Active Pipeline (Recruiting Now)365 (196)
Completed vs Stopped Early60 / 30 (4.5%)
Median Closed Actual Enrollment54 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Sun Yat-sen University
Hospital Research SiteLocationShared Protocols
Sun Yat-sen University Cancer CenterGuangzhou, Guangdong319
The First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou, Guangdong21
Hunan Cancer HospitalChangsha, Hunan13

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Sun Yat-sen University
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05918094Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/GastroesophagPhase IIIRECRUITING
NCT06726421Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)Phase IIIRECRUITING
NCT07477626Radiotherapy After Prostatectomy for Node Positive Prostate CancerPhase IIIRECRUITING
NCT06455410GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal CarcinomaPhase IIRECRUITING
NCT06301165TPC Versus GP Induction Chemotherapy for Nasopharyngeal CarcinomaPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Sun Yat-sen University Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI